FXN and Friedreich ataxia: DMF treatment has been shown to ameliorate disease hallmarks and symptoms in disease models (cellular and mouse models) not only in MS, but also in AD, PD, ALS, and in Friedreich’s ataxia (FA), an inherited neurodegenerative disorder resulting from decreased expression of the mitochondrial protein frataxin, for which there is no approved therapy [77].